PharmaEngine
智擎生技製藥股份有限公司
PharmaEngine is a Taiwan TPEx-listed biotechnology company; its most advanced asset is PEP02 / ONIVYDE (Commercialized, First- and second-line pancreatic ductal adenocarcinoma), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| PEP02 / ONIVYDE | — | Commercialized | First- and second-line pancreatic ductal adenocarcinoma | — | 2026-08-06 | Company disclosure |
| PEP07 | CHK1 inhibitor | Phase 1; recruiting | Acute Myeloid Leukemia; Lymphoma, Mantle-Cell | Australia, Taiwan | 2025-07-31 | Trial registry |
| PEP08 | PRMT5 inhibitor | Phase 1 dose escalation ongoing | Advanced or metastatic MTAP-deficient solid tumors | Australia, Taiwan, South Korea | 2026-08-06 | Company disclosure |
Key events
- PharmaEngine expects US$1.5 million in sublicense revenue (company disclosure)